Association of Cervical Effacement With the Rate of Cervical Change in Labor Among Nulliparous Women by Langen, Elizabeth S. et al.
Association of Cervical Effacement With the Rate of Cervical 
Change in Labor Among Nulliparous Women
Elizabeth S. Langen, M.D., Steven J. Weiner, M.S., Steven L. Bloom, M.D., Dwight J. Rouse, 
M.D., Michael W. Varner, M.D., Uma M. Reddy, M.D., M.P.H., Susan M. Ramin, M.D., Steve N. 
Caritis, M.D., Alan M. Peaceman, M.D., Yoram Sorokin, M.D., Anthony Sciscione, D.O., 
Marshall W. Carpenter, M.D., Brian M. Mercer, M.D., John M. Thorp Jr., M.D., Fergal D. 
Malone, M.D., Jay D. Iams, M.D., and for the Eunice Kennedy Shriver National Institute of 
Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) 
Network*
From the Departments of Obstetrics and Gynecology of Stanford University, Stanford, CA 
(E.S.L.); University of Texas Southwestern Medical Center, Dallas, TX (S.L.B.); University of 
Alabama at Birmingham, Birmingham, AL (D.J.R.); University of Utah Health Sciences Center, 
Salt Lake City, UT (M.W.V.); The University of Texas Health Science Center at Houston-Children’s 
Memorial Hermann Hospital, Houston, TX (S.M.R.); University of Pittsburgh, Pittsburgh, PA 
(S.N.C.); Northwestern University, Chicago, IL (A.M.P.); Wayne State University, Detroit, MI (Y.S.); 
Drexel University, Philadelphia, PA (A.S.); Brown University, Providence, RI (M.W.C.); MetroHealth 
Medical Center- Case Western Reserve University, Cleveland, OH (B.M.M.); University of North 
Carolina at Chapel Hill, Chapel Hill, NC (J.M.T.); Columbia University, New York, NY (F.D.M.); The 
Ohio State University, Columbus, OH (J.D.I.); and the George Washington University Biostatistics 
Center, Washington, DC (S.J.W.); and Eunice Kennedy Shriver National Institute of Child Health 
and Human Development, Bethesda, MD (U.M.R.)
Abstract
Objective—To assess the association of cervical effacement with the rate of intrapartum cervical 
change among nulliparous women.
Methods—We conducted a secondary analysis of a prospective trial of intrapartum fetal pulse 
oximetry. For women who had vaginal deliveries, interval censored regression was used to 
estimate the time to dilate at one centimeter intervals. For each given centimeter of progressive 
cervical dilation, women were divided into those who had achieved 100% cervical effacement and 
those who had not. The analysis was performed separately for women in spontaneous labor and 
those who were given oxytocin.
Results—Three thousand nine hundred two women were included in this analysis, 1,466 (38%) 
who underwent labor induction, 1,948 (50%) who underwent labor augmentation (combined for 
the analysis), as well as 488 (13%) who labored spontaneously. For women in spontaneous labor, 
the time to dilate 1 cm was shorter for those who were 100% effaced starting at 4 cm of cervical 
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dilation (P = 0.01 to P < 0.001). For women who received oxytocin, the time to dilate 1 cm was 
shorter for those who were 100% effaced throughout labor (P < 0.001).
Conclusion—The rate of cervical dilation among nulliparous women is associated with not only 
the degree of cervical dilation, but also with cervical effacement.
Clinical Trial Registration—ClinicalTrials.gov, www.clinicaltrials.gov, NCT00098709.
Précis
Achievement of 100% cervical effacement is associated with a shorter median time of dilation 
among nulliparous women.
Introduction
In recent years, the Consortium on Safe Labor (CSL) labor curves have replaced the 
traditional labor curve proposed by Friedman (1–3, 4). The importance of understanding 
normal labor progression was highlighted by Rouse and colleagues in 1999 when they 
challenged the idea that arrest of labor could be diagnosed after only 2 hours of inadequate 
cervical change (5). Rouse and colleagues found that 60% of women who were given 2 
additional hours to demonstrate cervical change went on to deliver vaginally. This 
observation highlighted that an inappropriate model of normal labor can lead to an over 
diagnosis of arrest disorders of labor and subsequently unnecessary cesarean deliveries. The 
American College of Obstetrics and Gynecology and the Society for Maternal-Fetal 
Medicine consensus statement on the Safe Prevention of the Primary Cesarean Delivery 
recommends using the CSL labor curves to define normal labor progress (6).
The CSL labor curve emphasizes the notion that active labor may not begin until 6 cm of 
cervical dilation. The CSL labor curve does not specifically address the role of cervical 
effacement in predicting normal rates of cervical change. Cervical effacement, however, has 
been used by many authors as a traditional part of the definition of active labor (7) and 
clinical experience would suggest that cervical effacement plays a role in labor progress. 
The current study assesses the association of cervical effacement with the rate of intrapartum 
cervical change among nulliparous women.
Materials and Methods
We conducted a secondary analysis of a prospective trial of fetal pulse oximetry conducted 
by the National Institute of Child Health and Human Development Maternal-Fetal Medicine 
Units Network (8). In the original study, women were eligible to participate if they were 
nulliparous with a singleton, cephalic, living fetus at or beyond 36 weeks of gestation. 
Exclusion criteria included a planned cesarean delivery, maternal temperature ≥38°C, 
maternal HIV or hepatitis infection, maternal heart or renal disease and diabetes mellitus 
requiring insulin. Women were enrolled with cervical dilations between 2 and 6 cm. Labor 
was managed according to the usual clinical practice at the participating centers. The 
original study was approved by the institutional review board at each participating Maternal-
Fetal Medicine Units Network center and written informed consent was obtained from each 
participant. Data were collected by trained research nurses.
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For the current study, we included all participants who had a vaginal delivery of a live-born 
infant. There were no stillbirths. A separate analysis included those participants who had a 
cesarean delivery for an arrest disorder. We abstracted data on patient race, body mass index, 
use of epidural anesthesia, use of oxytocin for labor induction or augmentation, use of 
cervical ripening agents, and details of labor progression including cervical dilation and 
effacement at each exam.
When comparing demographic and other patient characteristics between those with induced 
or augmented labor to those with spontaneous labor, the Wilcoxon rank-sum test was used to 
compare continuous variables, and categorical variables were compared by means of the chi-
square or Fisher's exact test, as appropriate. Analyses are presented separately for those with 
induced or augmented labor and those with spontaneous labor. Cervical effacement was 
recorded as a percentage of effacement (0–100%). Given that measurements of cervical 
effacement can often vary significantly by observer (9, 10) as well as the presumed clinical 
importance of achieving 100% cervical effacement, women were stratified into those who 
had achieved 100% cervical effacement and those who had not at each cervical exam. We 
used interval-censored regression to estimate the time to progress from one integer 
centimeter dilation to the next, assuming a log-normal distribution (11). Since cervical 
exams are often irregularly spaced, an individual may have progressed several centimeters of 
dilation from one exam to the next. Therefore, interval-censoring allows an estimation of the 
time between any two one-centimeter measurements (e.g., from 4 cm to 5 cm), even when 
those precise measurements were not observed for all patients. The median, 5th percentile, 
and 95th percentile were calculated for the time to progress between every two successive 
dilations, and the times for those at 100% effacement versus less than 100% effacement 
were compared with a Wald test using procedure LIFEREG in SAS Version 9.3. Using these 
same methods, a model was constructed with the covariates of 100% cervical effacement 
(yes vs. no), use of regional anesthesia (yes vs. no), maternal BMI, age, and race (white vs. 
all others). To calculate the cumulative time from 4 cm, 5 cm, and 6 cm to complete cervical 
dilation, right-censored regression assuming a log-normal distribution was used, with 
effacement assessed at the initial cervical dilation. Among women whose labor was induced, 
a model was constructed with additional terms for mechanical ripening, medical ripening, 
and their interactions with 100% cervical effacement. Finally, these analyses were repeated 
for the women who had cesarean deliveries for arrest disorders.
Results
The original trial randomized 5,341 women. Of these, 1,439 women had a cesarean delivery, 
leaving 3,902 women with vaginal deliveries in this analysis. There were no stillbirths. The 
current cohort included 1,466 (38%) women who underwent labor induction and 1,948 
(50%) who underwent labor augmentation with oxytocin (combined for the analysis), as 
well as 488 (13%) women who labored spontaneously. Women in spontaneous labor were 
different from those women who were augmented or induced in most baseline 
characteristics, though the absolute magnitude of the differences was small (Table 1). 
Missing information on cervical effacement was rare. Fewer than 1% of cervical 
examinations were missing an effacement measurement.
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For women who received oxytocin during labor, the time to dilate from each centimeter to 
the next was significantly shorter for women who were 100% effaced compared with those 
who were not (Table 2). For women who had spontaneous labor, the time to dilate from 2 to 
3 cm and 3 to 4 cm did not differ by effacement, while the time to dilate from 4 to 5 cm, 5 to 
6 cm, 6 to 7 cm, 7 to 8 cm, 8 to 9 cm and 9 to 10 cm was significantly shorter for those who 
were 100% effaced vs. those who were not (Table 2). When potential confounders including 
maternal race, age, BMI at the time of delivery, and use of regional anesthesia were 
considered in the model, the trend remained unchanged (Table 3).
For women who received oxytocin during labor, the time to reach 10 cm of cervical dilation 
from 4, 5, and 6 cm respectively was longer for those women who had not yet achieved 
100% cervical effacement at the starting dilation. For women in spontaneous labor, this was 
true for 4 and 5 cm of cervical dilation. However, the 100% cervical effacement at 6 cm 
dilation was not associated with a significantly shorter duration to reach 10 cm dilation 
(Table 4).
Among women whose labors were induced, 370 (25.2%) were medically ripened and 243 
(16.6%) were mechanically ripened. Medical ripening shortened the time to dilate from 6 to 
7 cm beyond the effect of 100% effacement (p=0.03), but not at other dilations. Mechanical 
ripening shortened the time to dilate from 9 to 10 cm beyond the effect of 100% effacement 
(p=0.01), but not at other dilations.
From the 1,439 women who had a cesarean delivery, we performed an analysis of the 985 
who delivered by cesarean for an arrest disorder in the first (n=773) or second (n=212) stage 
of labor, despite the use of oxytocin. Those women with 100% effacement had consistently 
faster rates of cervical dilation compared with those at less than 100% (Tables 5–6).
Discussion
Labor is defined as “uterine contractions that bring about demonstrable effacement and 
dilation of the cervix.” (12) While labor involves both dilation and effacement, existing labor 
curves demonstrate only the rate of cervical change in relationship to cervical dilation (1–4). 
We sought to investigate how cervical effacement might influence expectations of the rate of 
cervical change. In this large cohort of nulliparous women, the rate of cervical dilation in 
labor was significantly associated with achieving 100% cervical effacement.
Much attention has been paid to when the transition to active labor begins. The CSL data 
suggest that active labor may not begin until 6 cm (1, 6). This strict criterion, however, has 
been challenged by Cohen and Friedman who “discouraged the use of any specific degree of 
dilation for the identification of the active phase” (13). They argue that the timing of active 
labor depends on assessment of the individual patient, but is typically between 3 and 6 cm. 
Our observations suggest that combining the assessment of cervical dilation with cervical 
effacement may allow us to better define the beginning of active labor. If our findings are 
confirmed, future labor guidelines may wish to include the combination of cervical dilation 
and effacement when defining active labor.
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Our analyses consistently demonstrated that achievement of 100% cervical effacement was 
associated with faster labor progression. Even when the comparisons did not reach statistical 
significance, the trend was in this direction. The instances that were not statistically 
significant occurred in those with spontaneous labor, which were a minority of our cohort. In 
particular, the availability of data at earlier dilations was scarce in this group, likely 
secondary to fewer women in spontaneous labor having been admitted to labor and delivery 
prior to more advanced cervical dilations. Overall, these smaller numbers do limit our ability 
to comment on this group.
Strengths of this study include the prospective collection of data from a large number of 
nulliparous women from multiple institutions. However, measuring the rate of labor progress 
was not the focus of the study, and there was no protocol regarding the frequency of 
examinations or the experience level of those performing them. The uneven frequency is 
partially addressed through our statistical methods, but potential observer errors are not. By 
separating women into those who were 100% effaced vs. not, we hoped to eliminate some of 
the inter-observer variability that is inherent in measuring cervical effacement (9, 10). This 
decision was designed to provide more-reproducible results, while allowing us to provide 
insight into how cervical effacement is associated with labor progression.
While those who have cesarean deliveries for arrest disorders have slower labor progression, 
we wished to address the basic question regarding cervical effacement in this group as well. 
Therefore, we repeated the analysis in this group and found that the pattern of more rapid 
cervical dilation was associated with achievement of 100% cervical effacement in these 
women as well. While the absolute range of time to dilate from one centimeter to the next 
may differ between those with a vaginal or cesarean delivery, the association between rate of 
cervical change and 100% cervical effacement was consistently observed.
Our study is applicable only to women who share characteristics with the women in the 
original study. We do not have data on multiparous women or diabetic women. Also, our 
analysis was limited to those who arrived at the hospital and agreed to participate in the 
randomized trial before reaching 7 cm dilation. Those missed would include women whose 
labor was progressing more quickly and therefore without sufficient opportunity to enroll in 
the trial. The result is an unknown lengthening of the time we report for labor progression. 
Lastly, those who chose to participate in the randomized trial may be different from those 
who did not.
Finally, our analysis combined women who had labor inductions with those who had labor 
augmentations. This was done because the distinction between these groups can be difficult 
to make and there is likely substantial overlap. The combination of these two groups is 
supported by the findings by Harper and colleagues who analyzed the labor progress of 
women with augmented and induced labors and found them to be similar (14).
Labor involves a complex process of both cervical dilation and effacement. As we strive to 
safely reduce the number of unnecessary cesarean deliveries, we hope that an understanding 
of how cervical effacement may impact the expected rate of cervical change in labor will 
allow clinicians to more appropriately diagnose arrest disorders.
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Table 1
Patient demographics and labor characteristics *
Characteristic Overall
(n=3.902)
Induced/Augmented
(n=1,466/1.948)
Spontaneous
(n=488) p-value
†
Maternal race <0.001
  Black or African American 1,190 (30.5%) 1,051 (30.8%) 139 (28.5%)
  White 2,041 (52.3%) 1,856 (54.4%) 185 (37.9%)
  Other 671 (17.2%) 507 (14.9%) 164 (33.6%)
Ethnicity
  Hispanic/Latina 952 (24.4%) 756 (22.1%) 196 (40.2%) <0.001
Maternal age (years) 23.0 ± 5.2 23.3 ± 5.3 21.6 ± 4.6 <0.001
BMI at end of pregnancy
(kg/m2)
<0.001
  18.5–24.9 500 (12.9%) 405 (12.0%) 95 (19.6%)
  25–29.9 1,452 (37.5%) 1,263 (37.3%) 189 (39.1%)
  30–34.9 1,152 (29.8%) 1,026 (30.3%) 126 (26.0%)
  >=35 767 (19.8%) 693 (20.5%) 74 (15.3%)
  Mean/s.d. 30.9 ± 5.9 31.1 ± 5.9 29.8 ± 5.8
Gestational age at delivery
(weeks)
39.7 ± 1.3 39.7 ± 1.3 39.5 ± 1.2 <0.001
Regional anesthesia 3,695 (94.7%) 3,302 (96.7%) 393 (80.5%) <0.001
  Initiated before
  randomization
3,349 (85.8%) 3,027 (88.7%) 322 (66.0%) <0.001
Delivery method 0.002
  Spontaneous vaginal 3,122 (80.0%) 2,708 (79.3%) 414 (84.8%)
  Forceps 456 (11.7%) 403 (11.8%) 53 (10.9%)
  Vacuum 324 (8.3%) 303 (8.9%) 21 (4.3%)
Dilation at first exam (cm) 3 [2–4] 2 [1–3] 4 [3–4] <0.001
Effacement at first exam (%) 75 [50–90] 75 [50–90] 90 [80–100] <0.001
Number of cervical exams per
patient
6 [5–8] 7 [5–8] 5 [4–6] <0.001
Time from one exam to the
next (mins)
89 [52–140] 90 [52–140] 80 [45–125] <0.001
Birth weight (grams) 3,315 ± 445 3,323 ± 448 3,265 ± 421 0.001
BMI, body mass index
*
Data are mean ± standard deviation, n (%), or median [interquartile range]
†Comparing induced and augmented vs. spontaneous labors. Continuous variables compared using the Wilcoxon rank-sum test and categorical 
variables using the chi-square test.
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